Highlights BioAtla, Inc.

Equities

BCAB

US09077B1044

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-08 pm EDT			5-day change	1st Jan Change
1.27 ^USD	-3.79%		-5.93%	-48.37%

Jul. 01	BioAtla, Inc.(NasdaqGM:BCAB) dropped from Russell 3000E Value Index	CI
Jul. 01	BioAtla, Inc.(NasdaqGM:BCAB) added to Russell Microcap Growth Index	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

BioAtla, Inc. Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology Annual Meeting	May. 23	CI
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Ahead of Key Inflation, Retail Data	May. 15	MT
BioAtla Shares Jump 10% in Premarket Activity Wednesday as Diluted Net Loss Narrows in Q1	May. 15	MT
BioAtla, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors	May. 06	CI
BioAtla, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Bioatla Hosting Virtual R&D Day to Highlight Ba3071 Cab-Ctla-4 Phase 1 Data in Multiple Solid Tumor Types	Dec. 13	CI
BioAtla, Inc. Presents Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event	Dec. 05	CI
BioAtla, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
BioAtla, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-01	CI
BioAtla, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Viatris Projects Lower 2023 Revenue Despite Swinging to Fourth-Quarter Profit	23-02-27	MT
BioAtla Says US FDA Approves Investigational New Drug Application for BA3182 to Treat Adenocarcinoma	23-02-23	MT
Bioatla Announces FDA Clearance of Investigational New Drug Application for Ba3182, A Cab Epcamxcab-Cd3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma	23-02-23	CI
BioAtla, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-03	CI
BioAtla, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-09	CI
BioAtla, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-04	CI
BioAtla, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-28	CI
BioAlta, Bristol Myers Squibb Partnering on Potential Cancer Treatments	22-01-10	MT
Bioatla, Inc. Enters into a Clinical Collaboration with Bristol Myers Squibb to Investigate Bioatla's Two Lead CAB-ADC Candidates, BA3011 and BA3021, in Combination with Bristol Myers Squibb's Anti-PD-1 Therapy Opdivo	22-01-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights BioAtla, Inc.

Equities

BCAB

US09077B1044

Highlights

Filters